secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytomX Therapeutics, Inc. (CTMX)
CIK:        0001501989
Form:       8-K
Filed at:   2022-02-14T23:59:59+00:00
Accession:  0001193125-22-041752
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

CytomX CFO Carlos Campoy takes temporary leave; VP Chris Ogden to act as interim principal accounting officer
--------------------------------------------------------------------------------

- CFO Carlos Campoy begins temporary personal leave effective Feb 14, 2022, but remains CFO and principal financial officer.
- Chris Ogden, VP Finance and Accounting, designated as interim principal accounting officer.
- Ogden's annual base salary set at $315,270 with discretionary bonus target of 30% of salary.
- Ogden has severance agreement providing up to 9 months base salary plus benefits and prorated bonus.
- Ogden joined CytomX in Aug 2021 after 15 years at Eli Lilly, most recently as CFO of Lilly's diabetes division.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501989/000119312522041752/0001193125-22-041752-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501989/000119312522041752/d495623d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-041752

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer